Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trials

16 clinical trials for Head and Neck Squamous Cell Carcinoma HNSCC across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer — RECRUITING · PHASE1
• Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery — RECRUITING · NA
• A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC — RECRUITING · PHASE1
• Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing — RECRUITING
• [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas — RECRUITING · PHASE2
• Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy — RECRUITING · PHASE1
• GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study — RECRUITING · PHASE1
• Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinoma (HNSCC) — RECRUITING · NA
• VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma — RECRUITING · PHASE1
• Perioperative Finotonlimab Plus Chemotherapy in Untreated Stage II HNSCC — NOT_YET_RECRUITING · PHASE2
• CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma — NOT_YET_RECRUITING · PHASE2
• A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors — TERMINATED · PHASE1
• Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma — NOT_YET_RECRUITING · PHASE2
• Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial — NOT_YET_RECRUITING · PHASE3
• Exercise Therapy in Head and Neck Squamous Cell Carcinoma (HNSCC) — NOT_YET_RECRUITING · NA
• Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma — NOT_YET_RECRUITING · PHASE2

Refine this search